Latest Biotech News

Eli Lilly said a high dose of its gene-editing therapy VERV-102 cut cholesterol by 62% in participants in a phase 1 trial, an early readout aimed at LDL lowering with a potential one-time...

A multicenter randomized phase 2 trial dubbed DURABLE found that maintenance durvalumab plus anlotinib performed better than durvalumab monotherapy in extensive-stage small-cell lung cancer. The...

Ahead of the 2026 ASCO Annual Meeting, several trial updates released with pre-meeting abstracts spotlight both clinical and health-economic endpoints across gastrointestinal and genitourinary...

Researchers introduced pUniFind, a unified deep learning model designed to interpret peptide mass spectra without relying on separate feature extractors typical of conventional mass spectrometry...

A new industry-focused report warns that clinical operations burnout is undermining patient enrollment. The piece highlights how coordinators can become buried in documentation, scheduling, and...

Using spatial multi-omics, researchers mapped changing macrophage populations across MASLD progression and identified markers that could support patient stratification in clinical trials. The...

A perspective piece argues that AI is becoming the “front door” to healthcare, but access gaps risk leaving millions unable to use it. The commentary stresses that tool builders must design...

Beckman Coulter Life Sciences, a Danaher company, released the Echo 650 Plus Series acoustic liquid handlers with upgraded electronics and enhanced acoustic performance. The company highlighted a...

FDA has granted accelerated approval to Beqalzi (sonrotoclax), the first BCL-2 inhibitor specifically approved for relapsed or refractory mantle cell lymphoma in the US. The approval covers adults...

Eli Lilly reported early Phase 1 clinical data for VERV-102, a gene-editing therapy acquired from Verve Therapeutics, showing a dose-dependent reduction in cholesterol. In the company’s update,...

A multicenter randomized Phase 2 trial called DURABLE showed maintenance therapy with durvalumab plus anlotinib improved outcomes versus durvalumab alone in extensive-stage small-cell lung cancer...

Using spatial multi-omics, researchers identified shifting macrophage populations across the progression of MASLD and described markers that could support patient stratification in clinical...

A study published in Nature Communications linked the trajectories of metabolic and inflammatory biomarkers after a cancer diagnosis to later cardiovascular disease (CVD) risk. Researchers...

A new approach dubbed MiTo aims to track somatic cell lineage evolution by using mitochondrial single-cell multi-omics. The method is designed to trace how individual cells change phenotypically...

Isomorphic Labs unveiled the Isomorphic Labs Drug Design Engine (IsoDDE), describing it as a unified computational system that extends beyond structure-only modeling approaches. The company says...

Researchers reported that independent transcription start sites regulate isoform diversity of RBM20, shaping splicing programs in health. The study highlights how RNA-binding protein regulation...

A new study in human temporal lobe epilepsy (TLE) identifies thalamo-cortical synchrony as a driver of seizure dynamics. The work characterizes how coordinated activity patterns between thalamus...

Researchers developed a nanofiber-based self-adhesive electrode combining self-doped PEDOT and polyurethane, aiming to improve flexibility and skin/device attachment for biomedical electronics....

Isomorphic Labs previewed a new Isomorphic Labs Drug Design Engine (IsoDDE) that aims to move past AlphaFold-style structure prediction toward more actionable small-molecule design. The company...

A multicenter randomized phase II DURABLE trial reported evidence that a maintenance regimen of durvalumab plus anlotinib outperforms durvalumab monotherapy in extensive-stage small-cell lung...